A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. - Wikidata - awgldk - TriplyDB

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy.

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy.

http://www.wikidata.org/entity/Q34220632

about

Survivin: a unique target for tumor therapy Survivin - biology and potential as a therapeutic target in oncology Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma Nanoformulated cell-penetrating survivin mutant and its dual actions.Correction: A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy.Targeting survivin in cancer: novel drug development approaches.Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model.Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells Transduction of Recombinant M3-p53-R12 Protein Enhances Human Leukemia Cell Apoptosis.Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn.Recent Advances on Small-Molecule Survivin Inhibitors.Chimeric aptamers in cancer cell-targeted drug delivery Survivin signaling in clinical oncology: a multifaceted dragon.Nanotechnology based platforms for survivin targeted drug discovery.From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides.Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy.Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy.Recent advances in nanomedicine and survivin targeting in brain cancers.FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-XL cell survival genes.Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

P2860

Q26747332-34B6523D-6B25-4C3A-830E-78100189AE19 Q26864567-C141E5BA-3063-4686-AE5E-F73C85D946E1 Q28535017-71A65858-6558-4486-96DB-7BD607435C45 Q33904982-5377176D-C698-4CFF-898A-375960A93BFA Q34331247-218BBE04-00FB-4D1D-9D80-261A6CAF2D0F Q34954296-E7634DD8-EDFF-4FDB-A2C8-6793159B1D17 Q35073199-4E8146CF-7C3E-4F7F-B3BE-326A7F5FAC0E Q36746950-0016EE3E-55D5-4298-A662-1CFE298FBAF0 Q37068043-75CE9CFA-AE20-4E77-938E-16A36F62D6E3 Q37131750-14A5F4F0-4012-4074-A9AA-FCF652551AA8 Q37689286-56E3FB44-452C-4469-8600-C12B84DA1BF5 Q37939984-FB57A993-E0CA-4751-BFA5-76AEEEB7D30D Q38017923-8354D5A4-B991-473E-883E-E3656FE71E0E Q38040859-40CD5921-567D-4DC9-AD20-5A74D719CC64 Q38787128-E232F6A4-98AD-43C5-BE35-BBA06D1158C8 Q39596768-50B0CB3A-C98C-448E-AB19-16BB8D3AF669 Q42254068-A952968B-5C91-48D5-AF67-99AB493219AB Q47378913-B40B40F2-F571-41F5-AFCD-53A936802C08 Q47547132-B814507A-8CA8-4A63-A89B-8F2F1B391D0A Q51774995-7549F56E-BFFA-4620-8E14-1F55409FE51C Q52672878-5BD1F9F1-7D69-462B-B874-48C79C525197

P2860

A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy.

http://www.wikidata.org/entity/Q34220632

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@ast

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@en

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@nl

type

label

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@ast

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@en

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@nl

prefLabel

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@ast

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@en

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@nl

P1433

Q34220632-45E389A9-19B7-4CCD-9EAC-85500A978A1A

P1476

Q34220632-67F108B8-37AE-4844-8209-2B47D440DDF3

P2093

Q34220632-24833777-7B4A-4596-B737-3A66E2C8E01E

Q34220632-9A670298-A1D1-4B4A-BFC5-2DB3CD72E0E8

Q34220632-B6F8B552-091A-433B-8E6D-4BD918B5D2C0

Q34220632-C13BBCC5-8E50-4C62-B5D1-7735B0F5B952

P2860

Q34220632-074AE478-493E-4269-A682-8FA59D930E5B

Q34220632-08E1DA3F-8D3C-4F79-AB03-EEC56B15F1C4

Q34220632-0944E026-B9B0-4F1D-A9ED-502F8E988954

Q34220632-0D98C52A-AC8C-4D05-8C3D-57B9F3B95D9C

Q34220632-173E383A-C9C9-4E67-9C33-B2670AC71198

Q34220632-1745E6FE-99D3-4AFF-A767-458F4277CCD6

Q34220632-2119BEEA-4C76-493B-9F5B-2F9A6D482419

Q34220632-22D40A7C-C324-4A53-B653-1ECA71A92649

Q34220632-2A6A750F-7E63-49DF-BF1B-1A599DA0620C

Q34220632-4A00B150-184F-4F9F-8A47-4962AC807662

P2888

Q34220632-8225D6F6-E95F-41C8-BEFE-204A197C8A4C

P304

Q34220632-74A1AEBB-9A30-4505-9084-5301CCE9954D

P31

Q34220632-66093DE4-0648-423C-9D2F-7E8BE72DAAF6

P356

Q34220632-B7DA0AF3-39B8-4A59-8F92-7CC34239035B

P478

Q34220632-E78CD59A-E902-4619-938E-A36454A0857A

P50

Q34220632-A607317D-763F-4B68-A36A-8CDE8FF1CA00

Q34220632-C833D0C8-66DB-4C9B-AA9A-349E50FFCB3C

P577

Q34220632-1E263F7E-DD81-426A-B16C-680E1A078BC7

P5875

Q34220632-5D073DAB-3350-4979-A050-2A8A70B446A1

P6179

Q34220632-29E72211-EF47-4C00-B853-DF62AE60F64C

P698

Q34220632-48319BB5-198C-41F7-AD7D-76A6BAF97C5E

P921

Q34220632-2B91D82E-0D5B-444A-9FCE-99A0DAFCDCE6

P932

Q34220632-7A710C80-D5A5-43E1-AAFB-78145C751767

P356

1475-2867-10-36

P1433

Cancer Cell International

P1476

A cell-permeable dominant-nega ...... cancer cells to TNF-α therapy.

@en

P2093

Chun Hei Antonio Cheung

http://www.w3.org/2001/XMLSchema#string

Geoffrey W Krissansen

http://www.w3.org/2001/XMLSchema#string

Ji-Zhong Bai

http://www.w3.org/2001/XMLSchema#string

Liting Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Control of apoptosis and mitotic spindle checkpoint by survivin

Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement

Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

TNF-alpha induces two distinct caspase-8 activation pathways

Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin

A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy

An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7

IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs

Inhibition of melanoma tumor growth in vivo by survivin targeting.

P2888

1475-2867-10-36

P304

36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2867-10-36

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47335514

http://www.w3.org/2001/XMLSchema#string

P6179

1008388513

http://www.w3.org/2001/XMLSchema#string

P698

20920299

http://www.w3.org/2001/XMLSchema#string

P921

P932

2958862

http://www.w3.org/2001/XMLSchema#string